Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 5.48%
As of Thursday, September 10, Kalaris Therapeutics, Inc.’s KLRS share price has surged by 5.48%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Commentary & Analysis
Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Down 5.74%
As of Tuesday, September 08, Kalaris Therapeutics, Inc.’s KLRS share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 6.06%
As of Tuesday, August 18, Kalaris Therapeutics, Inc.’s KLRS share price has surged by 6.06%, which has investors questioning if this is right time to sell.Michael Rose
Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 5.93%
As of Friday, August 14, Kalaris Therapeutics, Inc.’s KLRS share price has surged by 5.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Down 5.79%
As of Wednesday, August 05, Kalaris Therapeutics, Inc.’s KLRS share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.5 | $257.9 | 18% |
|
| Shares Out (Mil) | 23.8 | 54.3 | 33% |
|
| Institutional Ownership | 72.9% | 92.9% | 44% |
|
| Float (Mil) | 7.3 | 41.4 | 15% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 73 | 674 | 31% |
|
| Price Change (52-week) |
(35.5%) | 51.5% | 24% |
|
| Growth | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.521) | ($2.008) | ($1.659) | |
| Month Ago EPS | ($0.521) | ($2.008) | ($1.659) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.518) | ($2.026) | ($1.626) | |
| Year/Year Chg | 7.6% | (29.4%) | (15.1%) | |
| Financials | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($44) | ($43) | 17% |
|
| EPS (TTM) | ($2.065) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($45) | $2 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | ($15) | $174 | 1% |
|
| Valuation | KLRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.21 | 2.51 | 31% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (46.0%) | (47.7%) | 12% |
|
| ROE | (79.9%) | (54.9%) | 11% |
|
| Liabilities to Assets | 42.1% | 29.1% | 33% |
|
| F-Score | 1 | 3 | 1% |
|
Kalaris Therapeutics, Inc. did not pass any screens on 9/25/2026.
